Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.

Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis

Open access
Xu, Manhong, Fan, Ruiyan, Fan, Xiaoe, Shao, Yan, Li, Xiaorong · 2022 · Drug Design, Development and Therapy

Abstract

Currently, the treatment for ocular neovascular diseases, including diabetic macular edema (DME) and age-related macular degeneration (AMD), mainly involves repeated intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs. Although it can preserve vision, repeated injections are an invasive treatment modality, leading to serious complications and reducing patient adherence to treatment. To reduce the frequency of administration, prolong the time of drug action, and avoid repeated intravitreal injections, the combination of sustained-release materials with anti-VEGF drug therapy has become an emphasis in ophthalmology. In this review, we highlight the current state of anti-VEGF technology, its challenges, and the sustained-release strategies under investigation or being used in clinical practice. Both continuous release and considerable therapeutic effects can be achieved by encapsulating anti-VEGF drugs in sustained-release materials to minimize the number of intravitreal injections. At present, two sustained-release materials are being tested in clinical research, and although basic research shows the strong therapeutic application prospects of extended-release drugs, its challenges mainly involve the discrepancy between the release rates in vitro and the efficiency of the drugs in vivo. Briefly, sustained release of anti-VEGF agents is an advantageous strategy for treating retinal angiogenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/dddt.s383101

Cites

145 of 145 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Development timeline of anti-VEGF agents applied in ocular fundus disease. Black: the time indicates the year of FDA approval for anti-VEGF drugs. Blue: the time represents the year of KSI-301 for phase 3 clinical trials. Grey: the time indicates the expanded ophthalmic application of anti-VEGF drugs.
Figure 1 Development timeline of anti-VEGF agents applied in ocular fundus disease. Black: the time indicates the year of FDA approval for anti-VEGF drugs. Blue: the time represents the year of KSI-301 for phase 3 clinical trials. Grey: the time indicates the expanded ophthalmic application of anti-VEGF drugs.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 145 references

Research works printed but not linked: 13

  1. Domańska-Janik, 1972, Neuropatol Pol, 10, 17
  2. Kim, 2018, Surv Ophthalmol, 63, 618, 10.1016/j.survophthal · doi:10.1016/j.survophthal
  3. Ferrara, 2006, Retina, 26, 859, 10.1097/01.iae.0000242842 · doi:10.1097/01.iae.0000242842
  4. Arrigo, 2021, Pharmaceutics, 13, 10.3390/pharmaceutics.13071102 · doi:10.3390/pharmaceutics.13071102
  5. Zhang, 2008, Mol Vis, 14, 37
  6. Chandrasekaran, 2021, Ther Adv Ophthalmol, 13, 25158414211027708, 10.1177/251.58414211027708 · doi:10.1177/251.58414211027708
  7. Liang, 2018, Invest Ophthalmol Vis Sci, 59, 211
  8. 2020, Angiogenesis, Exudation and Degeneration, 8 February 2020
  9. Tseng, 2012, J Glaucoma, 21, 241, 10.1097/ijg.0b013e31820.d7d19 · doi:10.1097/ijg.0b013e31820.d7d19
  10. Mouallem, 2016, Retina, 36, 2197, 10.1097/iae.0000.000000001062 · doi:10.1097/iae.0000.000000001062
  11. 2019, Hawaiian Eye & Retina Annual Meeting, January 21, 2019
  12. Pandit, 2017, Artif Cells Nanomed Biotechnol, 45, 1397, 10.1080/21691401.20161243545 · doi:10.1080/21691401.20161243545
  13. Nadarassan, 2014, Invest Ophthalmol Vis Sci, 55, 1950

Cited by

See all 118

Metadata

Authors
Xu, M., Fan, R., Fan, X., Shao, Y., & Li, X.
Affiliations
Tianjin Medical University Eye Hospital (CN)
Corresponding author
Li, Xiaorong
Venue
Drug Design, Development and Therapy
Published
2022-09
Volume
Volume 16
Pages
3241-3262
ISSN
1177-8881 (ISSN-L)
OpenAlex
W4296720485
Cited by
111
References
145
Citations by year
2026: 36 · 2025: 42 · 2024: 23 · 2023: 10
FWCI
4.03
Type
journal article
Language
en
Open access
Locations
  • Drug Design Development and Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (acceptedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
  • National Natural Science Foundation of China (82171085)
  • Natural Science Foundation of Tianjin City (19JCZDJC64000)
  • Tianjin Research Innovation Project for Postgraduate Students (2021YJSB271)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
Keywords
VEGF inhibitors, sustained drug release, retinal angiogenesis, diabetic macular edema, age-related macular degeneration, intravitreal injection, ocular neovascular disease, drug encapsulation
MeSH terms
Bevacizumab, Ranibizumab, Delayed-Action Preparations, Diabetic Retinopathy, Humans, Macular Edema, Neovascularization, Pathologic, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors, Intravitreal Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis. https://app.cochat.ai/papers/10.2147/dddt.s383101
The paper
Xu, M., Fan, R., Fan, X., Shao, Y., & Li, X. (2022). Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s383101

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.